BRITTANY LEATHERWOOD: Open Payments
NPI 1992429559 · HUMBLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$970 in 24 payments from 8 companies in 2025. Trend: 2023 $578 · 2024 $524 · 2025 $970
Food & beverage: $970
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $407 |
| Regeneron Healthcare Solutions, Inc. | 5 | $178 |
| GENZYME CORPORATION | 3 | $155 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $38 |
| Lilly USA, LLC | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| Optinose US, Inc. | 1 | $17 |
Products named: NUCALA, DUPIXENT, NEFFY, ZEPBOUND, TEZSPIRE, Xhance.
Industry payments across TX — which companies pay providers there.
